Total future deaths averted in the 2020-2035 period, and per 100,000 vaccinated
Total future cases averted in the 2020-2035 period, and per 100,000 vaccinated

Vaccine procurement cost per death averted
Vaccine procurement cost per case averted

Disproportionate impact of disease on vulnerable groups
Special benefits of vaccination for women and girls

Direct medical costs averted
Indirect costs averted

Epidemic potential of disease
Impact of vaccination on antimicrobial resistance (AMR)

Total under-five deaths averted in the 2020-2035 period, and per 100,000 vaccinated
Total DALYs averted in the 2020-2035 period, and per 100,000 vaccinated
Vaccine procurement cost per disability-adjusted life year (DALY) averted

Degree of vaccine market challenges
Potential for Gavi support to catalyse additional investment

Ease of supply chain integration
Need for healthcare worker behaviour change
Feasibility of vaccination time point
Acceptability in target population
Long-term financial implications

Optimal use of current and future alternative interventions (prevention and treatment)

No specific indicator – evaluated on a case-by-case basis 

Total procurement cost to Gavi and countries, 2020-2035

Incremental in-country operational costs per vaccinated person

Additional costs for introduction